Concepedia

Owen Pearson

OP

Statistics

Publications

22

Citations

1.9K

H-Index

18

Active since

2008

Affiliations

Swansea Bay University Health Board(Current)

Queen Mary University of London

University College London

University of Cambridge

Imperial College London

Owen Pearson is an author at Swansea Bay University Health Board specializing in multiple sclerosis, neurology, and multiple sclerosis therapy.

ORCID

Publications per year

2008–2025

22

Publications

22

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

J William L Brown, Alasdair Coles, Dana Horáková et al. · JAMA · 2019 · 547 citations · Full text

, , +14

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

, , +14

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Tomáš Kalinčík, J William L Brown, Neil P. Robertson et al. · The Lancet Neurology · 2017 · 162 citations · Full text

, , +16

Contribution of relapses to disability in multiple sclerosis

Claire Hirst, Gillian Ingram, Owen Pearson et al. · Journal of Neurology · 2008 · 137 citations

, , +10

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 110 citations

, , +11

1–5 of 22